Payment overview · 2025
General Payments
$350.26
19 reported records · 6 companies
Healthcare provider profile · identity verified
Jason Nicholas Prager, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · MORRISTOWN, NJ · NPI 1801047667
Verified facts
What the public records show
CMS Open Payments records show Jason Nicholas Prager, MD received $350.26 in general payments during 2025 across 19 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 695 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.92 | 22.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.76 | 22.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.85 | 21.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $57.00 | 16.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.89 | 12.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.84 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $350.26 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.92 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $74.85 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.69 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.69 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 695 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
695 | 96 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 202 |
| Eliquis | Apixaban | 695 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 119 |
| Escitalopram Oxalate | Escitalopram Oxalate | 356 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 105 |
| Mirtazapine | Mirtazapine | 345 | 94 |
| Gabapentin | Gabapentin | 331 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 92 |
| Losartan Potassium | Losartan Potassium | 276 | 77 |
| Sertraline Hcl | Sertraline Hcl | 249 | 75 |
| Trazodone Hcl | Trazodone Hcl | 223 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 69 |
| Donepezil Hcl | Donepezil Hcl | 191 | 45 |
| Metformin Hcl | Metformin Hcl | 179 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 44 |
| Furosemide | Furosemide | 176 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 44 |
| Lisinopril | Lisinopril | 152 | 39 |
| Alprazolam | Alprazolam | 147 | 57 |
| Divalproex Sodium | Divalproex Sodium | 135 | 31 |
| Torsemide | Torsemide | 135 | 43 |
| Carvedilol | Carvedilol | 131 | 31 |
| Allopurinol | Allopurinol | 122 | 32 |
| Omeprazole | Omeprazole | 115 | 33 |
| Famotidine | Famotidine | 112 | 29 |
| Simvastatin | Simvastatin | 107 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 26 |
| Clonazepam | Clonazepam | 101 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 22 |
| Prednisone | Prednisone | 99 | 56 |
| Potassium Chloride | Potassium Chloride | 96 | 32 |
| Memantine Hcl | Memantine Hcl | 90 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Latanoprost | Latanoprost | 81 | 19 |
| Risperidone | Risperidone | 81 | 12 |
| Tramadol Hcl | Tramadol Hcl | 81 | 24 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Finasteride | Finasteride | 77 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 21 |
| Pregabalin | Pregabalin | 67 | 20 |
| Nystatin | Nystatin | 64 | 32 |
| Alendronate Sodium | Alendronate Sodium | 63 | 16 |
| Azithromycin | Azithromycin | 60 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 35 |
| Midodrine Hcl | Midodrine Hcl | 56 | 16 |
| Levetiracetam | Levetiracetam | 55 | 11 |
| Montelukast Sodium | Montelukast Sodium | 54 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 27 |
| Warfarin Sodium | Warfarin Sodium | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 38 |
| Ozempic | Semaglutide | 52 | 14 |
| Spironolactone | Spironolactone | 52 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 40 |
| Lorazepam | Lorazepam | 51 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 12 |
| Cephalexin | Cephalexin | 45 | 27 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | 13 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Digoxin | Digoxin | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Cefuroxime | Cefuroxime Axetil | 33 | 26 |
| Enulose | Lactulose | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Amoxicillin | Amoxicillin | 30 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Xarelto | Rivaroxaban | 27 | 12 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 17 |
| Atenolol | Atenolol | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 15 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 13 |
| Topiramate | Topiramate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | 12 |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Carbatrol | Carbamazepine | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.26 · 19 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, KISUNLA, Leqembi, NURTEC ODT, PAXLOVID, PREVNAR 20, REXULTI, The Cologuard Plus Collection Kit, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error